Exhibit 10.15



 Exhibit 10.15 

[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

SPECIFIC RESEARCH COOPERATION AGREEMENT 

UPMC REF. NO.: C15/0855 

GENSIGHT REF. NO.: XXXX 
  

	1.	BY AND BETWEEN 

 Pierre et Marie Curie University (Paris 6), a French public, scientific,
cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 
 Hereinafter referred to as UPMC 

Represented by Professor Jean CHAMBAZ, President, 
 And

 Institut National de la Santé et de la Recherche Médicale (French National Institute of Health and Medical Research),
a French public, scientific and technical research establishment located at 101 rue de Tolbiac, 75013 PARIS 
 Hereinafter referred to as INSERM

 Represented by Mr. Yves Lévy, Chairman and Chief Executive Officer, 

And 
 The Centre National de la Recherche
Scientifique (National Center for Scientific Research), a French public scientific and technical research establishment located at 3-5 rue Michel Ange, 75794 Paris Cedex 16 

Hereinafter referred to as the CNRS 
 Represented by its
Director General, Mr. Alain FUCHS, 
 UPMC, the CNRS and INSERM acting both in their own name and in the name and on behalf of the Research
Center Institut de la Vision (Vision Institute), a joint research unit (UM 80) (UMRS 968 INSERM UPMC- UMR 7210 CNRS UPMC), directed by Professor José SAHEL. 

UPMC, the CNRS and INSERM being hereinafter jointly referred to as the ESTABLISHMENTS. 

UPMC has been authorized by the CNRS and INSERM to sign this Cooperation Agreement in its name and on its behalf. 







 OF THE FIRST PART, 

AND 
 GenSight Biologics, a French
Société Anonyme (Corporation), whose registered office is located at 74 rue du Faubourg Saint Antoine, 75012 Paris 

Hereinafter referred to as “GENSIGHT” 

Represented by Bernard GILLY, Chairman and CEO, 
 ON THE
SECOND PART, 
 The ESTABLISHMENTS and GENSIGHT are hereinafter individually referred to as a “Party” and collectively as the
“Parties”. 
 RECITALS: 
 GENSIGHT and
UPMC, acting on behalf of the ESTABLISHMENTS, signed on 19 December 2013, a certain cooperation agreement (hereinafter the “Cooperation Agreement”) allowing for the creation of a priority cooperation by and between GENSIGHT and the
LABORATORY for the performance of research work in the area of the targeting of mitochondria and treatment by gene therapy of Leber’s optic neuropathy as well as the vision restoration strategy using optogenetics in patients suffering from
retinitus pigmentosa or AMD. 
 Article 2 of the said Cooperation Agreement sets forth that the research work undertaken within the said framework shall be
covered by a specific agreement (hereinafter the “Specific Agreement”) specifying the rights and obligations applicable to the Parties in terms of ownership and use in keeping with the terms and conditions of the Cooperation Agreement,
with such Specific Agreement also detailing GENSIGHT’s financial contributions under the Cooperation Agreement, with schedules setting out the scientific program and the organization of the research, as well as the complete costs borne by the
LABORATORY on the one hand and GENSIGHT on the other hand. 
 The Parties thus entered into discussions in order to define, within the scope of a specific
cooperation agreement (hereinafter the “Specific Cooperation Agreement”) the implementing terms of the aforementioned research work. 
 NOW
THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS: 
 ARTICLE 1 - PURPOSE 

The purpose of this Specific Cooperation Agreement is to define: 
  

	•	 	the implementing terms of a research cooperation activity (hereinafter the “Research Cooperation Activity”) entitled “Development and set-up of devices for photostimulation of optogenetic proteins”
whose program is attached hereto as Schedule 1 (Scientific and technical schedule: Development and validation of informative glasses clinical prototypes for the stimulation of an optogenetically transfected retina) hereto (hereinafter the
“Project”); 

  

	•	 	the financial terms (Schedule 2), rights and obligations of the Parties and the rules applicable as regards the ownership and use of the results derived from the Project. 


  
 2 








 The Specific Cooperation Agreement is subject to the Cooperation Agreement which applies fully within the scope
of the Project and is attached hereto as Schedule 3. 
 Under the Specific Cooperation Agreement, the Parties are independent contractors. No provision of
the Specific Cooperation Agreement should be construed as involving any right or obligation for the Parties outside the scope of the Specific Cooperation Agreement and the Cooperation Agreement. 

ARTICLE 2 – DEPLOYED RESOURCES - ORGANISATION OF THE RESEARCH 

The deployed resources (personnel, biological material, intellectual property and identified prior knowledge, etc.) and the cost associated with the completion
of the Cooperation Activity, as defined in Article 1, are specified in the detailed Financial Schedule attached as Schedule 2 and forming an integral part of this Specific Cooperation Agreement. 

The Project shall be conducted within the LABORATORY by the LABORATORY’s Chief Science Officers, Ryan BENOSMAN and Guillaume CHENEGROS. 

As regards the Project, GENSIGHT’s scientific points of contact are as follows: Joel CHAVAS, Engineering Project Manager, and Didier PRUNEAU, Scientific
Director, and any other person appointed on an ad-hoc basis by GENSIGHT’s management, after considering the particular issue covered by this specific agreement. 

The Cooperation Activity shall be monitored within the scope of the Steering Committee in accordance with Article 3 of the Cooperation Agreement. 

The LABORATORY’s Chief Science Officers shall send to GENSIGHT intermediary reports describing the project’s progress, every [**] months, after the
execution of the Specific Cooperation Agreement, and shall submit a final report upon the Agreement’s expiration date. Highly specific attention shall be paid to the maintenance of the laboratory logs serving to record the Project’s
experiments and results. Subject to a notice period of [**] days, GENSIGHT shall be entitled to procure at its own expense the audit of such laboratory logs, by a third party appointed in order to ascertain whether the LABORATORY and the
ESTABLISHMENTS have duly complied with their contractual obligations hereunder. Such audit may only be conducted in strict compliance with the Chief Science Officers’ professional requirements and on the premises of the LABORATORY on which the
Research Cooperation Activities are conducted, for the sole purpose of ascertaining the proper completion thereof. 
 Such audit may only be conducted
within the following time slots: from 9 a.m. to 6 p.m., from Monday to Friday. 
 Should any circumstance prevent the Chief Science Officers from pursuing
the Cooperation Activities, the ESTABLISHMENTS agree to inform GENSIGHT forthwith in writing and to propose a replacement solution within [**] days. GENSIGHT shall be granted a period of [**] days in order to approve or reject the proposed solution.
Failing an agreement between the Parties concerning a replacement solution within [**] months from the date on which the Chief Science Officers no longer discharge their duties, GENSIGHT shall be entitled to terminate this Specific Cooperation
Agreement in accordance with Article 7 below. 
 [**] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. 

  
 3 








 Regarding the employees of the Parties who are assigned to the Project, the Parties agree to apply Article 4 of
the Cooperation Agreement. 
 ARTICLE 3 – RESPECTIVE FINANCIAL CONTRIBUTION OF THE PARTIES 

3.1 Each Party agrees to deploy the resources necessary in order to complete the Project. 

3.2 The Parties agree that the Cooperation Agreement executed between GENSIGHT and UPMC provides for the initial payment of a total amount of one million
forty-one thousand euro not including the value added tax (€1,041,000 not including VAT) by GENSIGHT to the ESTABLISHMENTS (see Article 9 of the Cooperation Agreement). Pursuant to a supplemental agreement (Ref. No. UPMC C14/0665A03) to the
said Cooperation Agreement, GENSIGHT’s total financial contribution is in the amount of two million two hundred nine thousand nine hundred fifty-seven euro not including the value added tax (€2,209,957 not including VAT), in accordance
with Article III. 
  Accordingly, in consideration for the undertakings assumed by the ESTABLISHMENTS under this Specific Cooperation Agreement with a
view to the completion of the Project, there shall be deducted, from the total amount allocated in the Cooperation Agreement, a total all-in amount of [**] euro not including the value added tax (€[**] not including VAT). The Parties agree that
UPMC’s management expenses shall be deducted from the financial revenues generated by the Specific Cooperation Agreement. The deductions made since the execution date of the Cooperation Agreement shall cover a period of [**] months/year as
follows: 
  

	•	 	€[**] not including VAT as of the execution date hereof 

  

	•	 	€[**] not including VAT as of 15 June 2016 

  

	•	 	€[**] not including VAT as of 15 June 2017 

  

	•	 	€[**] not including VAT as of 1 March 2018 

 In the event of any change to the VAT rate, the rate in
effect as of the date of the invoicing shall be applicable. 
 Invoices issued under the Cooperation Agreement shall specify the amounts allocated to this
Specific Cooperation Agreement by referring to this document’s technical and scientific schedule. 
 ARTICLE 4 - CONFIDENTIALITY - PUBLICATIONS -
COMMUNICATIONS 
 The Parties agree to apply Articles 10 and 11 of the Cooperation Agreement. 

ARTICLE 5 – OWNERSHIP OF RESULTS - PROTECTION OF THE JOINT RESULTS - OPERATING PROCEDURES IN RESPECT OF THE JOINT RESULTS 

The Parties agree to apply the provisions of Articles 5.3, 5.4, 6 and 7, and Schedule 3 “General Principles of Co-ownership” of the Cooperation
Agreement. 
 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 4 








 ARTICLE 6 - TERM 

This Specific Cooperation Agreement shall be effective from 15 March 2015 for a term of [**] months. 

Notwithstanding the above term, and regardless of the cause of termination of the Specific Cooperation Agreement, Articles 4 and 5 hereof, referring to
Articles 5.3, 5.4, 6, 7, 10, and 11 of the Cooperation Agreement shall survive the termination of this Specific Cooperation Agreement. 
 ARTICLE 7 -
TERMINATION 
  This Specific Cooperation Agreement may be terminated by either Party if the other Party fails to perform one or more of its
obligations under this Agreement and has not cured the relevant breach within one (1) month from notice thereof by registered mail, unless the defaulting Party proves that such default is attributable to an event of force majeure. 

The Party prevented from performing its contractual obligations because of the occurrence of an event of force majeure shall immediately inform the other
Party. Should such impossibility or late performance due to an event of force majeure continue after a period of [**] months, then such other Party may terminate this Agreement at any time by way of a written notice sent to the other Party. 

This Specific Cooperation Agreement shall also be terminated as a matter of law in case of winding-up or court-ordered liquidation of GENSIGHT effective from
the date of the court decision ordering such liquidation, subject to the provisions of Article L.621.28 of the French Commercial Code. 
 Also, the Specific
Cooperation Agreement may be terminated unilaterally by GENSIGHT, in accordance with the provisions of Article 2.2.1 of the Cooperation Agreement, in the event that the ESTABLISHMENTS fail to propose to GENSIGHT a new Chief Science Officer in
respect of the Agreement. 
 The exercise of the termination right shall not release the Parties from the duty to comply with the obligations until the
effective date of the Agreement’s termination. 
 In the event of early termination howsoever arising, any amounts due to UPMC shall be calculated on a
pro rata basis of the Research already completed by the LABORATORY by the Agreement’s termination date, it being understood that the amounts already paid by UPMC for the remuneration of the staff shall be reimbursed to UPMC in order to enable
UPMC to comply with its obligations vis-à-vis such staff remunerated within the scope of this Specific Cooperation Agreement. 
 ARTICLE 8
– NON-TRANSFERABILITY 
 The Parties agree to apply Article 13 of the Cooperation Agreement. 

ARTICLE 9 – SCHEDULES 
 The following
schedules: 
  

	 	•	 	Schedule 1: Description of the Research Cooperation Activity 

  

	 	•	 	Schedule 2: Budget of the Cooperation Activity 

  

	 	•	 	Schedule 3: Cooperation Agreement signed on 19 December 2013 form an integral part of the Specific Cooperation Agreement. 


[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 5 








 In case of conflict between the provisions of this Specific Cooperation Agreement and the provisions of the
Cooperation Agreement, the provisions of the Cooperation Agreement shall prevail. 
 In case of conflict between the provisions of this Specific Cooperation
Agreement and the provisions of Schedules 1 and 2, the provisions of the Specific Cooperation Agreement shall prevail. 
 ARTICLE 10 –
JURISDICTION AND APPLICABLE LAW 
 This Agreement shall be subject to French law. 

The Parties shall endeavor to amicably resolve any disputes arising from the interpretation or performance of the clauses of this Agreement. 

Should a disagreement persist after [**] months, the PARIS courts shall have jurisdiction. 

ARTICLE 11- MISCELLANEOUS 
 11.1 This Agreement may
not be amended unless by way of an instrument previously signed by the authorised representatives of the Parties. 
 11.2 Should any provision of this
Specific Cooperation Agreement be held invalid or unenforceable, in whole or in part, by any court of competent jurisdiction, the rest of the said provision and/or the other clauses of this Specific Cooperation Agreement shall remain fully valid and
effective. 
 11.3 The Parties represent that they are party to a currently valid insurance policy covering the financial consequences of the liability that
they may incur because of any bodily injury or tangible or intangible damage inflicted on another Party or on any third party in connection with the performance of this Specific Cooperation Agreement. The rule according to which “the State is
its own insurer” shall apply to the ESTABLISHMENTS. Accordingly, the ESTABLISHMENTS represent that their own budget shall cover any damage possibly resulting from their activity. 

Executed in Paris, on 
 In two original copies. 

For the President and by delegations, 
 Head of the Office of

 Business and Technology Transfer 
  

									
	For UPMC	 	 	 	For GENSIGHT BIOLOGICS
					
	Signature	 	 /s/ Sandrine Ayuso
	 		 	Signature	 	 /s/ Bernard Gilly

	Name:	 	Jean CHAMBAZ	 		 	Name:	 	Bernard GILLY
	Title:	 	President	 		 	Title:	 	Chairman and CEO
	Date:	 	 06/15/2015
	 		 		 	Date: 06/12/2015

 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.


  
 6 








       SIGNATURE of the Director of Institut de la
Vision 
  

			
	Signature      	 	 /s/ José-Alain Sahel

	Name:	 	José-Alain SAHEL
	Title:	 	Director of the Institut de la Vision Research Center
	Date:	 	
	
	    SIGNATURE of the Chief Science Officers
		
	Signature	 	 /s/ Ryad Bensosman

	Name:	 	Ryad BENSOSMAN
	Title:	 	Chief science officer
	Date:	 	
		
	Signature	 	 /s/ Guillaume Chenegros

	Name:	 	Guillaume CHENEGROS
	Title:	 	Chief science officer
	Date:	 	
		
	Signature	 	 /s/ Didier Pruneau

	Name:	 	Didier Pruneau
	Title:	 	Scientific Director – GenSight
	Date:	 	
		
	Signature	 	 /s/ Joel Chavas

	Name:	 	Joel Chavas
	Title:	 	Engineering Project Manager – GenSight
	Date:	 	


  
 7 








 SCHEDULE 1 

SCIENTIFIC AND TECHNICAL SCHEDULE 

[**] 
 [**] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 8 









	2.	SUMMARY OF THE PROJECT 

 [**] 

[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 9 









	3.	SCHEDULE 2 

 [**] 

[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 10 








 SCHEDULE 3 

COOPERATION AGREEMENT 

  
 11